Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ethical Drugs' Sales Remain Flat in May: Crecon Report
July 19, 2010
- Nippon Shinyaku to Start Clinical Trials for RNA Drugs in FY2013
July 19, 2010
- Procedures Changed for Applications Based on Data from Public Domain
July 19, 2010
- Rezaltas Remains No. 1 in HP Market
July 19, 2010
- 6 Firms to Receive Subsidies to Enhance New-Type Flu Vaccines Production Capacity
July 19, 2010
- JPMA Asks Member Companies Not to Talk about New Drug Development Premium
July 19, 2010
- Daiichi Sankyo to Integrate Ranbaxy's NDDR
July 19, 2010
- Pfizer's ALK Inhibitor to Be Launched in 2012: Dr Wagner of Kantar Health
July 19, 2010
- Seikagaku Submits Amended PMA for Gel-200 to the FDA
July 19, 2010
- Toa Eiyo: Sales of Long-Listed Drugs Continue to Drop
July 19, 2010
- Acquisition of New Platform Technologies Key for R&D: Dr Odaka of Takeda
July 19, 2010
- Number of DPC Hospitals Increases to 1,391
July 19, 2010
- Alfresa Pharma to Take Over Tofranil from Novartis
July 19, 2010
- Korosho to Create Subcommittee on Vaccines Not Covered by Periodic Programs
July 19, 2010
- AZ to Develop Promotional Methods Not Using MRs
July 19, 2010
- Korosho Announces Data on Subsidies Provided by Local Gov't for Vaccinations
July 19, 2010
- Shionogi Wins Patent Infringement Lawsuit over Crestor in US
July 19, 2010
- GL Published by Korosho for Evaluation of Oral Hypoglycemic Agents
July 19, 2010
- Astellas, Teva Reach Settlement Agreement on Vesicare Patent Lawsuit
July 19, 2010
- Merck to Develop Biosimilars: Dr Wiederrecht
July 19, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…